Indaptus Therapeutics stock analysis
Want to see INDP full AI Analyst Report?
Indaptus Therapeutics (INDP) Stock Price & Analysis
INDP Stock Chart & Stats
- Day’s Range
- $3.13 - $3.60
- 52-Week Range
- $0.92 - $5.96
- Previous Close
- $3.45
- Volume
- N/A
- Average Volume (3M)
- 324.88K
- Market Cap
- $509.96M
- Enterprise Value
- $275.85M
- Total Cash (Recent Filing)
- $30.60M
- Total Debt (Recent Filing)
- $0
- Price to Earnings (P/E)
- ―
- Beta
- 1.11
- Next Earnings
- May 13, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Decoy Immunotherapy Platform
A focused immunotherapy platform gives Indaptus a defined pathway for developing multiple treatment approaches in oncology. The ability to study Decoy20 both as a standalone therapy and alongside checkpoint inhibitors could broaden clinical utility and create several development opportunities over the next several quarters.
Very Low Leverage
The absence of debt limits interest obligations and refinancing exposure while the company funds clinical development. This provides greater flexibility than a highly leveraged balance sheet, allowing available capital to remain focused on research, operations, and potential program advancement.
Completed Capital Raise
Completion of the private placement provides a more concrete near-term funding resource for ongoing operations and development activities. Secured financing can reduce immediate liquidity pressure and give management additional time to advance its programs before another funding decision is required.
Bears Say
No Revenue And Persistent Losses
Indaptus remains entirely dependent on development progress rather than commercial product revenue, leaving earnings quality weak and financial performance loss-making. Without an approved revenue-generating product, the company has limited internal resources to fund operations and must rely on future financing or partnerships.
Negative Cash Generation
Persistent operating and free-cash-flow deficits indicate that the current business does not fund itself and must continue consuming capital to operate. Even with some improvement in cash burn, ongoing dependence on external funding can constrain development plans and increase shareholder financing risk.
Shareholder Dilution And Capital Erosion
The large share issuance expands the ownership base and can dilute existing holders, while the historical decline in stockholders’ equity reflects substantial capital erosion. Together, these factors show that funding operations has materially affected the equity base and may continue to do so.
Indaptus Therapeutics News
INDP FAQ
What was Indaptus Therapeutics’s price range in the past 12 months?
What is Indaptus Therapeutics’s market cap?
When is Indaptus Therapeutics’s upcoming earnings report date?
How were Indaptus Therapeutics’s earnings last quarter?
Is Indaptus Therapeutics overvalued?
Does Indaptus Therapeutics pay dividends?
What is Indaptus Therapeutics’s EPS estimate?
How many shares outstanding does Indaptus Therapeutics have?
What happened to Indaptus Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Indaptus Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Indaptus Therapeutics Stock Smart Score
Company Description
Indaptus Therapeutics
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Junyi Dai
- Employees
- 5
- Website
- indaptusrx.com
- Address
- 3 Columbus Circle, New York City, NY, 10019, US
Indaptus Therapeutics (INDP) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 5 | 1 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 12 | 0 | 0 |












